Earlier this month, peer-reviewed medical journal The Lancet published an interim analysis from the Phase III trial of the Russian Sputnik V vaccine, showing its 91.6 percent efficacy against symptomatic COVID-19.
Earlier this month, peer-reviewed medical journal The Lancet published an interim analysis from the Phase III trial of the Russian Sputnik V vaccine, showing its 91.6 percent efficacy against symptomatic COVID-19.